Dr Reddy's completes acquisition of Teva's US portfolio of 8 products

Posted on:05 Aug 2016 09:43:23

Dr Reddy's completes acquisition of Teva's US portfolio of 8 products
05 August 2016 Current Affairs GK: Dr Reddy's announced that it has successfully completed the acquisition of eight Abbreviated New Drug Applications (ANDAs) in the US from Teva Pharmaceuticals Industries and an affiliate of Allergan Plc.

The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of acquisition of Allergan's generics business. In June, the company had entered an agreement with Teva to buy this portfolio of ANDAs for $ 350 million.

Dr Reddy's recently said some of these products would start adding to its top line some time in 2018. The portfolio is a mix of six ANDAs pending approval, one approved ANDA and one ANDA with tentative approval, and comprises complex generic products across diverse dosage forms. 

The combined sales of branded versions of products in the US were approximately $ 3.5 billion for the recent twelve months ending June 2016, according to IMS Health.

The products include Buprenorphine HCL/Naloxone HCL Sublingual Film(generic equivalent to Suboxone), Ethinyl estradiol/Ethonogestrel Vaginal Ring(generic equivalent of NuvaRing), Exetimibe/Simvastatin tablets (generic equivalent to Kombiglyze XR), Tobramycin Inhalation Solution(generic equivalent to Tobi), Phentermine HCL/Topiramate ER Capsules(generic equivalent to Qsymia), Imiquimod Topical Cream(generic equivalent to Zyclara 3.75 % Cream), and Ramelteon Tablets(generic equivalent to Rozerem).

Gk Current Affairs April 2017

26 APRIL
NEWS
25 APRIL
NEWS
24 APRIL
NEWS
22 APRIL
NEWS

Gk Current Affairs March 2017

31 MARCH
NEWS
30 MARCH
NEWS
29 MARCH
NEWS
28 MARCH
NEWS

Gk Current Affairs February 2017

28 FEBRUARY
NEWS
27 FEBRUARY
NEWS
25 FEBRUARY
NEWS
24 FEBRUARY
NEWS




Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.